JP2005501532A5 - - Google Patents

Download PDF

Info

Publication number
JP2005501532A5
JP2005501532A5 JP2003506300A JP2003506300A JP2005501532A5 JP 2005501532 A5 JP2005501532 A5 JP 2005501532A5 JP 2003506300 A JP2003506300 A JP 2003506300A JP 2003506300 A JP2003506300 A JP 2003506300A JP 2005501532 A5 JP2005501532 A5 JP 2005501532A5
Authority
JP
Japan
Prior art keywords
antigens
examples
derived
pathogens
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003506300A
Other languages
English (en)
Other versions
JP2005501532A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/017374 external-priority patent/WO2002102828A2/en
Publication of JP2005501532A publication Critical patent/JP2005501532A/ja
Publication of JP2005501532A5 publication Critical patent/JP2005501532A5/ja
Pending legal-status Critical Current

Links

Description































(表2)抗原/ペプチドが由来する病原体の例
Figure 2005501532
Figure 2005501532















(表3)ウイルスの選択用抗原の例
Figure 2005501532
















(表4)上記ウイルス/抗原に由来するB細胞およびT細胞のエピトープの例
Figure 2005501532





JP2003506300A 2001-06-01 2002-05-31 キメラフラビウイルスベクター Pending JP2005501532A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29526501P 2001-06-01 2001-06-01
PCT/US2002/017374 WO2002102828A2 (en) 2001-06-01 2002-05-31 Chimeric flavivirus vectors

Publications (2)

Publication Number Publication Date
JP2005501532A JP2005501532A (ja) 2005-01-20
JP2005501532A5 true JP2005501532A5 (ja) 2010-03-25

Family

ID=23136958

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003506300A Pending JP2005501532A (ja) 2001-06-01 2002-05-31 キメラフラビウイルスベクター

Country Status (11)

Country Link
US (2) US7569383B2 (ja)
EP (1) EP1401859B1 (ja)
JP (1) JP2005501532A (ja)
KR (1) KR100921592B1 (ja)
CN (1) CN1551782A (ja)
AU (1) AU2002322026B2 (ja)
BR (1) BR0210907A (ja)
CA (1) CA2448971C (ja)
ES (1) ES2439724T3 (ja)
PL (1) PL371187A1 (ja)
WO (1) WO2002102828A2 (ja)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
US7569383B2 (en) 2001-06-01 2009-08-04 Acambis Inc. Chimeric flavivirus vectors
BR122018075730B1 (pt) * 2002-01-15 2022-04-19 Acambis, Inc Flavivírus na preparação de uma composição de vacina e composição de vacina
US20050002968A1 (en) * 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
WO2003101397A2 (en) * 2002-05-31 2003-12-11 Acambis, Inc. Tetravalent dengue vaccines
MXPA05005140A (es) * 2002-11-15 2005-08-19 Acambis Inc Vacuna contra el virus del nilo occidental.
BRPI0714721A2 (pt) * 2006-07-14 2013-04-24 Sanofi Pasteur Biologics Co construÇço de vacinas de vÍrus recombinante por inserÇço direta mediada por transpàson de determinantes imunolàgicos estranhos em proteÍnas de vÍrus vetorial
EP2069483A4 (en) * 2006-09-29 2010-10-27 Sanofi Pasteur Biologics Co RECOMBINANT RHINOVIRAL VECTORS
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
BRPI0718548A2 (pt) 2006-11-07 2013-11-12 Sanofi Pasteur Biologics Co Estabilização de vacinas por liofilização
CA2676775A1 (en) * 2007-01-31 2008-09-25 Sanofi Pasteur Biologics Co. Flavivirus vaccine vector against influenza virus
WO2009030872A1 (en) * 2007-09-07 2009-03-12 Mats Axel Atterdag Persson Materials and methods for the treatment of hepatitis c
CA2716399C (en) 2008-03-05 2020-07-21 Pierre Chouvenc Process for stabilizing an adjuvant containing vaccine composition
SG188891A1 (en) 2008-03-14 2013-04-30 Sanofi Pasteur Biologics Co Replication-defective flavivirus vaccines and vaccine vectors
CN102089003A (zh) * 2008-03-27 2011-06-08 赛诺菲巴斯德生物制剂公司 重组鼻病毒载体
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
US20120128713A1 (en) * 2009-03-16 2012-05-24 Sanofi Pasteur Limited Replication-Defective Flavivirus Vaccine Vectors Against Respiratory Syncytial Virus
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
WO2013063248A1 (en) * 2011-10-25 2013-05-02 Florida Gulf Coast University Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes
WO2014016362A1 (en) 2012-07-24 2014-01-30 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
SG11201500412TA (en) 2012-07-24 2015-02-27 Sanofi Pasteur Vaccine compositions
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
CN103352029A (zh) * 2013-07-29 2013-10-16 中国人民解放军军事医学科学院微生物流行病研究所 一种乙脑/森林脑炎嵌合病毒及其应用
EP3158061B1 (en) * 2014-06-20 2019-08-07 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Chimeric west nile/dengue viruses and methods of use
AU2015310951A1 (en) 2014-09-02 2017-03-16 Sanofi Pasteur Vaccine compositions against dengue virus diseases
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
WO2017005652A1 (en) 2015-07-03 2017-01-12 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
BE1024160B9 (fr) 2015-12-22 2017-12-06 Glaxosmithkline Biologicals Sa Formulation immunogène
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
SG11201908280SA (en) 2017-03-30 2019-10-30 Univ Queensland "chimeric molecules and uses thereof"
WO2019040994A1 (en) 2017-09-01 2019-03-07 The Australian National University IMMUNOREGULATOR MOLECULES AND USES THEREOF
JP7313345B2 (ja) 2017-10-05 2023-07-24 サノフィ・パスツール デング熱に対するブースターワクチン接種のための組成物
CN111798712B (zh) * 2020-07-15 2021-10-29 周晓庆 噬菌体侵染细菌3d智能模拟方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
ES2140418T3 (es) 1991-09-19 2000-03-01 Us Health Flavivirus quimericos y/o flavivirus de crecimiento restringido.
US6136561A (en) 1995-05-24 2000-10-24 Hawaii Biotechnology Group, Inc. Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
KR100517323B1 (ko) 1997-02-28 2005-09-27 아캠비스 인코포레이티드 키메라 플라비바이러스 백신
BRPI9701774B8 (pt) 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US6416763B1 (en) 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
WO2001013743A1 (en) * 1999-08-20 2001-03-01 Wisconsin Alumni Research Foundation ASPARTIC AND MALIC ACID INHIBITION OF β-GLUCURONIDASE
AU1813901A (en) 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
GB2372991B (en) * 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
US7569383B2 (en) * 2001-06-01 2009-08-04 Acambis Inc. Chimeric flavivirus vectors
US6682883B1 (en) 2001-07-19 2004-01-27 Acambis, Inc. Diagnosis of flavivirus infection
JP5164305B2 (ja) 2001-10-19 2013-03-21 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 動物におけるフラビウイルス感染を予防および治療する方法
BR122018075730B1 (pt) 2002-01-15 2022-04-19 Acambis, Inc Flavivírus na preparação de uma composição de vacina e composição de vacina
US20050002968A1 (en) 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
WO2003101397A2 (en) 2002-05-31 2003-12-11 Acambis, Inc. Tetravalent dengue vaccines
MXPA05005140A (es) 2002-11-15 2005-08-19 Acambis Inc Vacuna contra el virus del nilo occidental.
US7189403B2 (en) 2003-06-30 2007-03-13 Institut Pasteur Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
WO2005040390A1 (fr) 2003-07-21 2005-05-06 Shanghai Tengen Biomedical Co., Ltd. Vaccin recombine utilisant le virus de la fievre jaune comme vecteur
WO2005049815A1 (en) 2003-11-21 2005-06-02 K.U.Leuven Research & Development Flavivirus replication
EP1809325B1 (en) 2004-10-20 2013-11-20 Sanofi Pasteur Biologics, LLC Vaccines against japanese encephalitis virus
CA2605924A1 (en) 2005-04-24 2006-11-02 Acambis Inc. Recombinant flavivirus vaccines
BRPI0504945B8 (pt) 2005-10-31 2022-08-02 Fundacao Oswaldo Cruz Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.

Similar Documents

Publication Publication Date Title
JP2005501532A5 (ja)
UA85536C2 (en) Viral antigens
DK1113816T3 (da) Influenzavirus-vaccinesammensætning
MA24422A1 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotrachaite infectieuse aviaire.
JP2004538039A5 (ja)
DE69532369D1 (de) Rekombinantes infektiöses nicht-in-Segmente-geteiltes, negativ-Strange-RNS-Virus
JP2002524024A5 (ja)
EP1741782A3 (en) Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
IS7830A (is) Bóluefni gegn lifrarbólgu C veiru (HCV)
ATE455791T1 (de) T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon
ATE489967T1 (de) Hcv-vakzin
IL158428A0 (en) Vaccine composition comprising at least one hiv virus antigen
JP2005511495A5 (ja)
JP2003160581A5 (ja)
ATE440960T1 (de) T-helferzellen-epitope
ATE455124T1 (de) Rekombinante vesicular stomatitis viren als impstoff gegen virale hämorrhagische fieber
IS7775A (is) DNA bóluefni sem umritar að minnsta kosti tvö óformgerð árprótín af vörtuveiru
ATE392903T1 (de) Impfstoff gegen pferdeherpesvirus
JP2005534326A5 (ja)
DK1002092T3 (da) Mimotoper af hypervariabel region 1 af E2-glycoproteinet fra HCV og anvendelser deraf
JP2005517783A5 (ja)
NO20022147L (no) Mimetiske peptider for epitope av apolipoprotein B-100, konkatamer og modifiserte peptider derav, og vaksinesammensetningsom omfatter det samme
JP2007516701A5 (ja)
WO2002026785A3 (de) Cd4+ t-lymphozyten spezifische hepatitis c virus-epitope
RU2000125255A (ru) 2',3'-дидегидро-2',3'-дидезокситимидин-5'[(этоксикарбонил)(этил)фосфонат]- ингибитор репродукции вируса иммунодефицита человека